Bio-Techne Corp Stock Price, News & Analysis

Bio-Techne Corporation (NASDAQ: TECH) has introduced new automated co-detection assays for the Roche DISCOVER ULTRA Platform, expanding its RNAscope ISH technology. These assays will allow simultaneous RNA and protein detection in tissue samples, potentially enhancing research in various diseases. The RNAscope platform is noted for its specificity and sensitivity, supported by over 6,600 peer-reviewed publications. With an expansive catalog of probes, Bio-Techne aims to accelerate research and therapeutic development in tissue diagnostics.

ScaleReady, a joint venture involving Bio-Techne (NASDAQ: TECH), announces the launch of the Cue Cell Processing System, designed exclusively for cell and gene therapy organizations. This innovative system automates complex, labor-intensive tasks, enhancing precision in cell processing workflows. Cue is customizable, ensuring that final formulations meet specifications consistently. Available in the U.S., Canada, and Europe, it also supports requests for regulatory documentation for advanced applications. This launch positions ScaleReady as a leader in the evolving market of cell and gene therapies.

Bio-Techne Corporation (NASDAQ: TECH) has initiated legal action against Molecular Instruments, Inc. in the UK, claiming infringement of its patented RNAscope® ISH technology. The lawsuit targets Molecular Instruments' HCR 3.0 technology, alleging violations of its European Patents 2,500,439 and 1,910,572. Bio-Techne's RNAscope® technology, known for its reliability in spatial biology, has over 6,000 peer-reviewed publications and 40,000 catalog probes. The company emphasizes the importance of protecting its intellectual property, which it views as critical for innovation and research advancement.

Bio-Techne Corporation (NASDAQ: TECH) presented new data regarding the Maurice Flex™ instrument at the 2022 CE Pharm conference, showcasing its advanced icIEF fractionation capabilities. This instrument addresses challenges in traditional ion-exchange chromatography (IEX) by offering rapid and high-purity fraction collection (80-100%) for intact mass spectrometry analysis. The instrument will allow scientists to choose their methods for downstream charge isoform characterization, streamlining protein analysis. The Maurice Flex™ is set to be launched for purchase in early 2023.

Bio-Techne Corporation (NASDAQ: TECH) announced that Exosome Diagnostics will present initial data on a non-invasive saliva profiling assay for Sjögren's Syndrome at the 15th International Symposium on Sjögren's Syndrome in Rome, Italy, on September 9, 2022. This novel assay utilizes extracellular vesicles to monitor RNA from saliva samples, offering a potential breakthrough in diagnosing and understanding this autoimmune disease. The study demonstrated high accuracy, with AUC values over 0.9. The development of this liquid biopsy tool aims to enhance precision medicine and improve patient care.

Bio-Techne Corporation (NASDAQ: TECH) announced that CEO Chuck Kummeth will present at the Baird 2022 Global Healthcare Conference on September 14, 2022, at 12:50 p.m. EST. The live webcast will be available on their Investor Relations website. Bio-Techne specializes in high-quality purified proteins, reagents, and genomic tools, generating approximately $1.1 billion in net sales in fiscal 2022. Their extensive product portfolio supports researchers and clinical labs in drug discovery and molecular diagnostics.

Bio-Techne Corporation (NASDAQ: TECH) announced plans to seek shareholder approval for a four-for-one forward stock split during its 2022 Annual Meeting scheduled for October 27, 2022. This initiative aims to increase the total number of authorized shares through an amendment to the Company's Articles of Incorporation, with the stock dividend expected in the second quarter of fiscal 2023. Shareholders will find more information in the preliminary proxy filed with the SEC on September 1, 2022, and additional details are forthcoming in a definitive proxy statement.

Bio-Techne Corporation (NASDAQ: TECH) announced that Jim Hippel, CFO, will present at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 1:30 p.m. EST. Interested parties can access the live webcast through the Investor Relations website. Bio-Techne specializes in high-quality purified proteins, diagnostics, and genomic tools, generating approximately $1.1 billion in net sales in fiscal 2022. The company employs about 3,000 individuals worldwide, focusing on advancing research and clinical diagnostics.